Vestnik dermatologii i venerologiiVestnik dermatologii i venerologiiВестник дерматологии и венерологии0042-46092313-6294Rossijskoe Obschestvo Dermatovenerologov i Kosmetologov121710.25208/vdv1217CLINICAL PRACTICE GUIDELINESКЛИНИЧЕСКИЕ РЕКОМЕНДАЦИИReview ArticleClinical evidence of therapy for genital psoriasis by biologic agentsДоказательные аспекты терапии псориаза гениталий с использованием генно-инженерной биологической терапииhttps://orcid.org/0000-0001-7610-606123669241000AAL-7772-20206807-7137SokolovskiyEvgeny V.СоколовскийЕвгений Владиславович
Russian Federation

MD, Dr. Sci. (Med.), Professor, Head of the Department of Dermatovenereology

д.м.н., профессор, заведующий кафедрой дерматовенерологии с клиникой

s40@mail.ruhttps://orcid.org/0000-0001-6353-66443470-9306KokhanMuza M.КоханМуза Михайловна
Russian Federation

MD, Dr. Sci. (Med.), Professor, Head of the Scientific Clinical Department of Dermatology

д.м.н., профессор, руководитель научного клинического отдела дерматологии

mkokhan@yandex.ruFirst Pavlov State Medical University of Saint PetersburgПервый Санкт-Петербургский государственный медицинский университет им. акад. И.П. ПавловаUral Scientific Research Institute of Dermatovenerology and ImmunopathologyУральский научно-исследовательский институт дерматовенерологии и иммунопатологии2804202197250552402202104032021Copyright ©; 2021, Sokolovskiy E.V., Kokhan M.M.Copyright ©; 2021, Соколовский Е.В., Кохан М.М.2021Sokolovskiy E.V., Kokhan M.M.Соколовский Е.В., Кохан М.М.https://creativecommons.org/licenses/by/4.0https://vestnikdv.ru/jour/article/view/1217

Data in the scientific literature on the use of biologic therapy in localized forms of psoriasis elucidate mostly the problems of treatment of palmoplantar, scalp psoriasis and nail psoriasis. At the same time, the number of scientific data on the effect of biological therapy on genital psoriasis is extremely limited. Important that the quality of life on patients with genital psoriasis has very low level, which indicates a significant influence on the psychological and social well-being. At the same time, the limited number of therapeutic approaches makes this problem even more urgent. Unfortunately, special clinical trials for such patients are rather an exception. Ixekizumab has been reported an effectiveness for patients with anogenital psoriasis. New data on the comparative efficacy of ixekizumab and secukinumab give hope us for new opportunity for the treatment of genital psoriasis.

Имеющиеся литературные данные о применении генно-инженерных биологических препаратов для лечения так называемого проблемного псориаза (псориаза с поражением определенных анатомических зон, при котором качество жизни пациента резко снижается) освещают большей частью проблемы терапии псориаза ладонно-подошвенного, волосистой части головы и псориатической ониходистрофии. При этом число научных данных о влиянии биологической терапии при псориазе с локализацией в области гениталий крайне ограниченно. Важно, что качество жизни пациентов с псориазом гениталий имеет очень низкие показатели, что говорит о значительном влиянии данной формы на психологическое и социальное благополучие. В то же время ограниченные возможности терапевтических подходов делают данную проблему еще более актуальной. Специальные исследования у данной категории пациентов являются, скорее, исключением. Ранее сообщалось об эффективности иксекизумаба у пациентов с псориазом аногенитальной локализации. Новые данные по сравнительной эффективности иксекизумаба и секукинумаба вселяют надежду на новые возможности терапии псориаза половых органов.

genital psoriasisixekizumabsecukinumabsexual dysfunctionгенитальный псориазиксекизумабсекукинумабсексуальная дисфункцияThe work was done and published through financing at the place of work of the authorsРабота выполнена и опубликована за счет финансирования по месту работы авторовNestle FO, Kaplan DH, Barker J. Psoriasis. N Engl J Med. 2009;361:496–509. doi: 10.1056/NEJMra0804595Krueger JG, Bowcock A. Psoriasis pathophysiology: current concepts of pathogenesis. Ann Rheum Dis. 2005;64(Suppl 2):ii30-ii36. doi: 10.1136/ard.2004.031120Griffiths CE, Barker JN. Pathogenesis and clinical features of psoriasis. Lancet. 2007;370:263–271. doi: 10.1016/S0140-6736(07)61128-3Schon MP, Boehncke WH. Psoriasis. N Engl J Med. 2005;352:1899–1912. doi: 10.1056/NEJMra041320Ryan C, Sadlier M, De Vol E, et al. Genital psoriasis is associated with significant impairment in quality of life and sexual functioning. J Am Acad Dermatol. 2015;72:978–983. doi: 10.1016/j.jaad.2015.02.1127Cather JC, Ryan C, Meeuwis K, et al. Patients’ perspectives on the impact of genital psoriasis: a qualitative study. Dermatol Ther. 2017;7:447–461. doi: 10.1007/s13555-017-0204-3Meeuwis KA, de Hullu JA, Massuger LF, et al. Genital psoriasis:a systematic literature review on this hidden skin disease. Acta Derm Venereol. 2011;91:5–11. doi: 10.2340/00015555-0988Merola JF, Breakman AP, Gottlieb AB, et al. The static physician’s global assesment of genitalia: a clinical outcome measure for the Severity of genital psoriasis. J Drug Dermatol. 2017;16(8):793–799.Guenther L, Han C, Szapary P, et al. Impact of ustekinumab on health-related quality of life and sexual difficulties associated with psoriasis: results from two phase III clinical trials. J Eur Acad Dermatol Venereol. 2011;25(7):851–857. doi: 10.1111/j.1468-3083.2011.04082.xMolina-Leyva A, Salvador-Rodriguez L, Martinez-Lopez A, et al. Association between psoriasis and sexual and erectile dysfunction in epidemiologic studies: a systematic review. JAMA Dermatol. 2019;1;155(1):98-106. doi: 10.1001/jamadermatol.2018.3442.Molina-Leyva A, Almodovar-Real A, Carrascosa JC, et al. Distribution pattern of psoriasis, anxiety and depression as possible causes of sexual dysfunction in patients with moderate to severe psoriasis. Ann Bras Dermatol. 2015;90(3):338–345. doi: 10.1590/abd1806-4841.20153254Ryan C, Sadlier M, De Vol E, et al. Genital psoriasis is associated with significant impairment in quality of life and sexual functioning. J Am Acad Dermatol. 2015;72:978–983. doi: 10.1016/j.jaad.2015.02.1127Schmid-Ott G, Kuensebeck HW, Jaeger B, et al. Validity study for the stigmatization experience in atopic dermatitis and psoriatic patients. Acta Derm Venereol. 1999;79:443–447. doi: 10.1080/000155599750009870Meeuwis KA, de Hullu JA, van de Nieuwenhof HP, et al. Quality of life and sexual health in patients with genital psoriasis. Br J Dermatol. 2011;164:1247–1255. doi: 10.1111/j.1365-2133.2011.10249.xLebwohl M, Amy Krupnick Freeman, Shane Chapman M, et al. Tacrolimus Ointment Study Group. Tacrolimus ointment is effective for facial and intertriginous psoriasis. J Am Acad Dermatol. 2004;51(5):723–730. doi: 10.1016/j.jaad.2004.07.011Liao YH, Tseng YS, Tsai TF. Comparison of cutaneous tolerance and efficacy of calcitriol 3 μg g−1 ointment and tacrolimus 0·3 mg g−1 ointment in chronic plaque psoriasis involving facial or genitofemoral areas: a double-blind, randomized controlled trial. Br J Dermatol. 2007;157(5):1005–1012. doi.org/10.1111/j.1365-2133.2007.08201.xKleyn CE, Woodcock D, Sharpe G. The efficacy of 01% tacrolimus ointment compared with clobetasone butyrate 005% ointment in patients with facial, flexural or genital psoriasis: P-41. Br J Dermatol. 2005;153:33. doi.org/10.1111/j.1365-2133.2005.06747.xKapila S, Bradford J, Fischer G. Vulvar psoriasis in adults and children: a clinical audit of 194 cases and review of the literature. J Lower Genit Tract Dis. 2012;16:364–371. doi: 10.1097/LGT.0b013e31824b9e5eBeck KM, Yang EJ, Sanchez IM, Liao W. Treatment of genital psoriasis: a systematic review Dermatol Ther (Heidelb). 2018;8:509–525. doi: 10.1007/s13555-018-0257-yКовалёва Ю.С. Генитальные дерматозы неинфекционной этиологии у мужчин. Эффективная фармакотерапия. 2019;15(10):34–39. [Kovaleva YuS. Genital dermatoses of non-infectious etiology in men. Effective pharmacotherapy. 2019;15(10):34–39 (In Russ.)]. doi: 10.33978/2307-3586-2019-15-10-34-39Theodosiou G, Svensson A. Methotrexate-associated sexual dysfunction: two case reports. Acta Derm Venereol. 2017;2;97(9):1132–1133. doi: 10.2340/00015555-2714Wylie G, Evans CD, Gupta G. Reduced libido and erectile dysfunction: rarely reported side-effects of methotrexate. Clin Exp Dermatol. 2009;34(7):e234. doi: 10.1111/j.1365-2230.2008.03082.xRyan C, Menter A, Guenther L, et al. Efficacy and safety of ixekizumab in a randomized, double-blinded, placebo-controlled phase IIIb study of patients with moderate-to-severe genital psoriasis. Br J Dermatol. 2018;179(4):844–852. doi: 10.1111/bjd.16736.Paller AS, Seyger MMB, Alejandro Magariños G, et al. Efficacy and safety of ixekizumab in a phase III, randomized, double-blind, placebo-controlled study in paediatric patients with moderate-to-severe plaque psoriasis (IXORA-PEDS). Br J Dermatol. 2020;183:231–241. doi: 10.1111/bjd.19147Al Mutairi N, Eassa BI: A Randomized Controlled Ixekizumab Vs Secukinumab trial to study the Impact on sexual activity in adult patients with genital psoriasis, Expert Opin Biol Ther. Published on-line 09 Nov 2020. doi: 10.1080/14712598.2021.1843629Parisi R, Symmons DP, Griffiths CE, et al. Global epidemiology of psoriasis: a systematic review of incidence and prevalence. J Invest Dermatol. 2013;133:377–385. doi: org/10.1038/jid.2012.339Burlando M, Herzum A, Carmisciano L, et al. Biologic therapy in genital psoriasis in women. Dermatologic Therapy. 2019;33(1):e13110. doi: 10.1111/dth.13110